TrialNature communications2025

Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Melinda Soeung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.